FDA blazes the transparency trail
This article was originally published in Scrip
There has been no shortage of moves to increase transparency at regulatory agencies in the past year or so. The European Medicines Agency has brought in new policies on access to documents and clinical trial data, while side-effect data is to be made more easily available. The French regulator, meanwhile, has promised zero tolerance on conflicts of interest among its committee members and more transparency on publishing minutes of its committee meetings.
You may also be interested in...
Valneva is scaling up manufacture of its coronavirus vaccine alongside the clinical development program, with a view to meeting its commitment to provide millions of doses for use in the UK and the EU.
The UK government says it will begin a consultation on a future falsified medicines scheme for Great Britain within a year after the passage of new legislation on medicines and medical devices. Moves are also under way to ensure the smooth supply of medicines from GB to Cyprus, Ireland, Malta and Northern Ireland.
The team behind Russia’s first COVID-19 vaccine has asked for scientific advice from EU drug regulators in view of a possible submission for marketing authorization.